|
US3773778A
(en)
|
1972-01-24 |
1973-11-20 |
Squibb & Sons Inc |
Sulfur derivatives of pyrazolo (3,4-b)pyridines
|
|
US4107288A
(en)
|
1974-09-18 |
1978-08-15 |
Pharmaceutical Society Of Victoria |
Injectable compositions, nanoparticles useful therein, and process of manufacturing same
|
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
SI9620103A
(sl)
|
1995-07-06 |
1998-10-31 |
Novartis Ag |
Pirolopirimidini in postopki za njihovo pripravo
|
|
EP1248869A2
(en)
*
|
2000-01-07 |
2002-10-16 |
Transform Pharmaceuticals, Inc. |
High-throughput formation, identification, and analysis of diverse solid-forms
|
|
ATE369854T1
(de)
|
2001-10-19 |
2007-09-15 |
Ortho Mcneil Pharm Inc |
2-phenyl benzimidazole und imidazo-[4,5]-pyridine als cds1/chk2-inhibitoren und adjuvantien in der chemotherapie oder strahlungstherapie zur behandlung von krebs
|
|
BR0213562A
(pt)
|
2001-10-26 |
2004-08-31 |
Aventis Pharma Inc |
Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
|
|
JP2005515173A
(ja)
|
2001-10-31 |
2005-05-26 |
バイエル・ヘルスケア・アクチェンゲゼルシャフト |
ピリミド［４，５−ｂ］インドール誘導体
|
|
EP1501514B1
(en)
|
2002-05-03 |
2012-12-19 |
Exelixis, Inc. |
Protein kinase modulators and methods of use
|
|
US7202244B2
(en)
|
2002-05-29 |
2007-04-10 |
Millennium Pharmaceuticals, Inc. |
Chk-1 inhibitors
|
|
WO2005011597A2
(en)
|
2003-07-29 |
2005-02-10 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
AU2004279427B2
(en)
|
2003-10-08 |
2008-07-03 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
JP4845736B2
(ja)
|
2003-10-14 |
2011-12-28 |
アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ |
プロテインキナーゼ阻害剤
|
|
US7691866B2
(en)
|
2003-10-16 |
2010-04-06 |
Novartis Vaccines And Diagnostics, Inc. |
2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
|
|
US20050096324A1
(en)
|
2003-11-05 |
2005-05-05 |
Zhi-Fu Tao |
Macrocyclic kinase inhibitors
|
|
US7163939B2
(en)
|
2003-11-05 |
2007-01-16 |
Abbott Laboratories |
Macrocyclic kinase inhibitors
|
|
CA2561831A1
(en)
|
2004-04-13 |
2005-12-22 |
Icagen, Inc. |
Polycyclic pyrazines as potassium ion channel modulators
|
|
CN1243033C
(zh)
|
2004-07-15 |
2006-02-22 |
合肥工业大学 |
一种通过内增韧制备薄膜级聚l－乳酸共聚物的方法
|
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
|
CA2604284A1
(en)
|
2005-04-28 |
2006-11-02 |
Supergen, Inc. |
Protein kinase inhibitors
|
|
CN101213187B
(zh)
|
2005-06-28 |
2012-06-06 |
塞诺菲-安万特股份有限公司 |
作为rho-激酶抑制剂的异喹啉衍生物
|
|
TWI387592B
(zh)
|
2005-08-30 |
2013-03-01 |
Novartis Ag |
經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
|
|
JP5052518B2
(ja)
|
2005-10-06 |
2012-10-17 |
シェーリング コーポレイション |
プロテインキナーゼインヒビターとしてのピラゾロピリミジン
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
GB0616747D0
(en)
|
2006-08-24 |
2006-10-04 |
Astrazeneca Ab |
Novel compounds
|
|
SA07280004B1
(ar)
|
2006-02-02 |
2011-10-29 |
استرازينيكا ايه بي |
ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
|
|
MX2009005964A
(es)
|
2006-12-27 |
2009-06-15 |
Sanofi Aventis |
Derivados de isoquinolina sustituidos con cicloalquilamina.
|
|
EP2727909A1
(en)
|
2007-03-16 |
2014-05-07 |
The Scripps Research Institute |
Inhibitors of focal adhesion kinase
|
|
WO2008117050A1
(en)
|
2007-03-27 |
2008-10-02 |
Astrazeneca Ab |
Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
|
|
US20100249112A1
(en)
|
2007-05-25 |
2010-09-30 |
Astrazeneca R&D |
Combination of chk and parp inhibitors for the treatment of cancers
|
|
US8618121B2
(en)
|
2007-07-02 |
2013-12-31 |
Cancer Research Technology Limited |
9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
|
|
GB0719644D0
(en)
|
2007-10-05 |
2007-11-14 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
US9000027B2
(en)
|
2008-02-04 |
2015-04-07 |
Dana-Farber Cancer Institute, Inc. |
Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3
|
|
GB0803018D0
(en)
|
2008-02-19 |
2008-03-26 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
US8481557B2
(en)
|
2009-04-11 |
2013-07-09 |
Array Biopharma Inc. |
Method of treatment using checkpoint kinase 1 inhibitors
|
|
US8865726B2
(en)
*
|
2009-09-03 |
2014-10-21 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors
|
|
US9012464B2
(en)
|
2010-11-25 |
2015-04-21 |
Ratiopharm Gmbh |
Salts and polymorphic forms of Afatinib
|
|
WO2013039854A1
(en)
|
2011-09-15 |
2013-03-21 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
|
JP6073910B2
(ja)
|
2011-11-09 |
2017-02-01 |
キャンサー・リサーチ・テクノロジー・リミテッド |
５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
|
|
EP2793882A4
(en)
|
2011-12-22 |
2015-04-29 |
Threshold Pharmaceuticals Inc |
ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
|
|
WO2013103836A2
(en)
|
2012-01-05 |
2013-07-11 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer
|
|
ES2624307T3
(es)
|
2012-05-15 |
2017-07-13 |
Cancer Research Technology Ltd |
5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo
|
|
CN102675858A
(zh)
|
2012-05-22 |
2012-09-19 |
同济大学 |
一种具有形状记忆功能可降解泪管栓塞的制备方法
|
|
GB201316526D0
(en)
|
2013-09-17 |
2013-10-30 |
King S College London |
Biomarkers
|
|
WO2015077602A1
(en)
|
2013-11-22 |
2015-05-28 |
Fred Hutchinson Cancer Research Center |
Methods for identifying therapeutic targets and treating and monitoring cancers
|
|
WO2015176033A1
(en)
|
2014-05-15 |
2015-11-19 |
Bristol-Myers Squibb Company |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
EP3347026A4
(en)
|
2015-09-09 |
2019-05-08 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
GENEMANIPULATION OF MACROPHAGES FOR IMMUNOTHERAPY
|
|
CA3015913A1
(en)
|
2016-02-29 |
2017-09-08 |
Foundation Medicine, Inc. |
Methods of treating cancer
|
|
WO2018102613A2
(en)
|
2016-12-01 |
2018-06-07 |
Nantomics, Llc |
Tumor antigenicity processing and presentation
|
|
JP7273791B2
(ja)
|
2017-04-10 |
2023-05-15 |
シエラ オンコロジー， インコーポレイテッド |
腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法
|
|
WO2018191299A1
(en)
|
2017-04-10 |
2018-10-18 |
Sierra Oncology, Inc. |
Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
|
|
CA3065803A1
(en)
|
2017-06-01 |
2018-12-06 |
Sierra Oncology, Inc. |
Biomarkers and patient selection strategies
|
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
|
|
CA3092079A1
(en)
|
2018-02-26 |
2019-08-29 |
Sierra Oncology, Inc. |
Methods of treatment of cancer comprising chk1 inhibitors
|
|
CA3135165A1
(en)
|
2019-03-28 |
2020-10-01 |
Sierra Oncology, Inc. |
Methods of treating cancer with chk1 inhibitors
|
|
MX2021013905A
(es)
|
2019-05-14 |
2022-05-18 |
Sierra Oncology Inc |
Métodos de tratamiento del cáncer mediante el uso de inhibidores de chk1.
|
|
TW202204348A
(zh)
|
2020-04-07 |
2022-02-01 |
美商西爾拉癌症醫學公司 |
Ｃｈｋ１抑制劑之合成方法
|